Nav: Home

First in-vivo trial of subharmonic contrast-enhanced imaging for detection of PCa

May 06, 2019

Leesburg, VA, May 6, 2019--A new technique for imaging of microbubble ultrasound contrast agents may be useful in detection of prostate cancer (PCa) not found by multiparametric magnetic resonance imaging (MRI), according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The first in vivo application of contrast-enhanced SHI in the prostate, the pilot study was conducted to evaluate contrast-enhanced subharmonic imaging (SHI) of the prostate for detection of PCa.

Building on the authors' previous work demonstrating the effectiveness of contrast enhanced harmonic imaging (HI) for detection of prostate cancer, 55 patients referred for prostate biopsy were imaged using conventional grayscale, color, and power Doppler, conventional contrast HI, SHI -- a new technique for imaging of microbubble ultrasound contrast agents with up to a 10-fold increase in contrast-to-background signal ratio relative to conventional HI -- and flash replenishment in combination with SHI (MIP-SHI).

The results demonstrated contrast-enhanced SHI enhancement in all patients. Detection of PCa using contrast-enhanced SHI included 9 of 31 patients with a prior negative MRI or negative MRI-guided biopsy, suggesting SHI may be useful in detection of PCa not found by multiparametric MRI.

"Diagnosis of clinically significant prostate cancer with non-invasive means is a real clinical challenge," said author of the study Ethan Halpern, MD. " Although multi-parametric MRI is currently used for this purpose, ultrasound has numerous advantages. Ultrasound systems are portable. Ultrasound studies are far less expensive and more widely available as compared with MRI. Contrast enhanced ultrasound studies can be performed at the same sitting as the ultrasound-guided biopsy, while mp-MRI requires two visits, one for the diagnostic MR study and a second for the fusion biopsy. There is no need for a fusion imaging system (additional hardware/software) when using contrast enhanced ultrasound. No additional effort is required to properly register the contrast-enhanced ultrasound diagnostic study with the targeting system for biopsy. Combining contrast enhanced ultrasound with subharmonic imaging has the potential to provide a new, non-invasive method for diagnosis and characterization of prostate cancer."
-end-
With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

American Roentgen Ray Society

Related Prostate Cancer Articles:

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
More Prostate Cancer News and Prostate Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...